T2 Biosystems announced that its Innovative Technology contract with Vizient has been extended through March 31, 2024. The products covered under the contract with Vizient include the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood. Through the extended contract, Vizient members will continue to have access to broader exposure and contracted pricing for the T2Dx Instrument and its corresponding panels that detect sepsis-causing bacterial and fungal pathogens.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TTOO:
- T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.
- T2 Biosystems highlights peer-reviewed article on COVID-19, sepsis
- T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy
- T2 Biosystems backs FY22 revenue view $22M-$23M, consensus $26.33M
- T2 Biosystems reports Q3 EPS ($2.95), consensus ($2.04)
